Source: Medscape, June 2025
Today I’m going to discuss a little bit of the controversy that is ongoing in terms of what is the best therapy for patients who have a stage III melanoma and BRAF mutation. What kind of therapy in the adjuvant setting should we give to these patients? To address this question, we have recently published a review in terms of real-world data comparing these two therapies.
Why did we do that? First, because these two therapies are approved for patients who have a BRAF mutation and there are no head-to-head comparisons that have been performed in clinical trials. Most likely, they will not be performed in the future because both therapies are approved in stage III; therefore, there is not really a big interest from the companies to perform this comparison in a head-to-head study.